Hormonal
GLP-1 receptor agonists (GLP-1 RAs) including dulaglutide, subcutaneous semaglutide, and oral semaglutide produce significant weight loss and BMI reduction in patients with type 2 diabetes and obesity, with oral semaglutide achieving the highest proportion of patients reaching the clinically significant ≥5% weight loss threshold.
GLP-1 medications like dulaglutide and semaglutide (oral and injectable) are effective for weight loss in people with type 2 diabetes and obesity. In this study, about half of the patients lost at least 5% of their body weight in just 3 months. Oral semaglutide was the most effective at getting patients to this 5% threshold. However, gastrointestinal side effects are common, and many patients do not reach the maximum dose. If you tolerate the medication, reaching the maximum dose is linked to better weight loss results. Consult your doctor about titration to maximize benefits.
GLP1 RA significantly reduced body weight (−4.95 kg, p < 0.001) and BMI (−1.86 kg/m2, p < 0.001)... Oral semaglutide achieved the highest reduction: 61.1 % of patients achieving ≥ 5 %, subcutaneous semaglutide 45.8 % and dulaglutide 40.6 %.
Why this rating
Observational, non-randomized, multicenter study with a small sample size (n=94) and short follow-up (3 months).
Source
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
José Seijas‐Amigo et al. · Primary care diabetes · 2023
DOI 10.1016/j.pcd.2023.05.004
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →